Braun J, et al. - Via a historical cohort in patients with ankylosing spondylitis (AS), the contributors set to compare radiographic progression among the cohort of those treated for up to 2 years with secukinumab (MEASURE 1) and with a historical cohort of biologic-naïve patients treated with NSAIDs (ENRADAS). A total of 168 patients from the MEASURE 1 cohort and 69 from the ENRADAS cohort were included. Across all cutoffs for no radiographic progression, the proportion of patients with no radiographic progression was noted consistently higher in the MEASURE 1 vs ENRADAS cohort. A numerical, but statistically non-significant, higher proportion of non-progressors and lower change in mSASSS over 2 years was demonstrated in patients treated with secukinumab in comparison to biologic-naïve patients treated with NSAIDs cohort.